Article Versions Notes

Tay E, Nguyen T-H, Ford L, Williams HD, Benameur H, Scammells PJ, Porter CJH. Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure. Pharmaceutics. 2020; 12(1):17. https://doi.org/10.3390/pharmaceutics12010017

Tay, Erin, Tri-Hung Nguyen, Leigh Ford, Hywel D. Williams, Hassan Benameur, Peter J. Scammells, and Christopher J. H. Porter. 2020. "Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure" Pharmaceutics 12, no. 1: 17. https://doi.org/10.3390/pharmaceutics12010017

Tay, E., Nguyen, T. -H., Ford, L., Williams, H. D., Benameur, H., Scammells, P. J., & Porter, C. J. H. (2020). Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure. Pharmaceutics, 12(1), 17. https://doi.org/10.3390/pharmaceutics12010017